Company intelligence / Profile preview

Lighthouse Pharmaceuticals

San Francisco, California, United Stateslighthousepharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

LHP588, their lead compound, has completed Phase 1 SAD/MAD studies demonstrating safety and tolerability with no serious adverse events. The FDA has cleared their IND application to proceed with the Phase 2 SPRING trial for P. gingivalis-positive Alzheimer's disease.

Therapeutic areas: CardiovascularOtherOncologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

LHP842

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Quince Therapeutics (acquired protease inhibitor portfolio from them)

Beyond the preview

Go deeper on Lighthouse Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lighthouse Pharmaceuticals.

Explore the full profile